The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients.

Matthew TorrePatrick Y WenJ Bryan Iorgulescu

Published in: Neuro-oncology practice (2022)

promoter unmethylation, partial methylation was predictive of improved OS among IDH-wildtype glioblastoma patients treated with first-line single-agent chemotherapy-supporting the use of temozolomide therapy in these patients.

Keyphrases

end stage renal disease
newly diagnosed
dna methylation
wild type
chronic kidney disease
peritoneal dialysis
gene expression
stem cells
squamous cell carcinoma
prognostic factors
radiation therapy
transcription factor
patient reported outcomes
cell therapy